# The Branded Health Service Medicines (Costs) (Amendment) Regulations 2026

S.I. 2026/614 · made 9 June 2026

These Regulations amend the Branded Health Service Medicines (Costs) Regulations 2018 (S.I. 2018/345) (the “Statutory Scheme Regulations”). The Statutory Scheme Regulations, amongst other matters, make a scheme for the purpose of requiring specific manufacturers and suppliers of branded medicines for health service use to pay certain amounts to the Secretary of State. These amounts are calculated by reference to the net sales income or estimated net sales income from supplies of such medicines. These amendments update the payment percentages for 2026 and subsequent years.

Made under: National Health Service Act 2006 (Section 263, Section 264, Section 266, Section 272)

PDFs: Printed copy https://openlegislation.uk/branded-health-service-medicines-costs-amendment-regulations-2026/pdf/uksi_20260614_en.pdf; UK Explanatory Memorandum https://openlegislation.uk/branded-health-service-medicines-costs-amendment-regulations-2026/pdf/uksiem_20260614_en_001.pdf

## Introductory text

NATIONAL HEALTH SERVICE, ENGLAND AND WALES
NATIONAL HEALTH SERVICE, SCOTLAND
HEALTH AND PERSONAL SOCIAL SERVICES, NORTHERN IRELAND
Made 9th June 2026
Laid before Parliament 10th June 2026
Coming into force 1st July 2026
The Secretary of State for Health and Social Care makes the following Regulations in exercise of the powers conferred by sections 263(1)(b) and (c), (2) and (5), 264(3), 266(1) and 272(7)(a) and (b) and (8) of the National Health Service Act 2006 having had regard to the matters specified in section 266(3), (4) and (4A) of that Act.
The Secretary of State has consulted in accordance with sections 263(1) and (1A) of that Act.

## 1 Citation, commencement and extent

(1) These Regulations may be cited as the Branded Health Service Medicines (Costs) (Amendment) Regulations 2026 and come into force on 1st July 2026.
(2) These Regulations extend to England and Wales, Scotland and Northern Ireland.

## 2 Amendments to the Branded Health Service Medicines (Costs) Regulations 2018

(1) Regulation 3 (payment scheme) of the Branded Health Service Medicines (Costs) Regulations 2018 is amended as follows.
(2) In paragraph (1), for the table substitute the following table—
“
Table
Applicable Period
Newer presentation payment percentage
Older presentation payment percentage
1st July 2026 to the end of 2026
16.5%
11%
1st January 2027 to the end of 2027 and any subsequent calendar year
16.5%
10.9%
”.
(3) In paragraph (1AB)—
(a) for “1st July 2025 and ending at the end of 2025”, substitute “1st July 2026 and ending at the end of 2026”; and
(b) for “31.3% and not 23.4%”, substitute “8.7% and not 16.5%”.
(4) In paragraph (1AC)—
(a) for “1st July 2025 and ending at the end of 2025”, substitute “1st July 2026 and ending at the end of 2026”;
(b) in sub-paragraph (a), for “1st January 2025 and ending at the end of 30 June 2025”, substitute “1st January 2026 and ending at the end of 30 June 2026”; and
(c) in sub-paragraph (b), for “15.5%”, substitute “24.3%”.

## Signature

Signed by the authority of the Secretary of State for Health and Social Care
Preet Kaur Gill
Parliamentary Under-Secretary of State
9th June 2026
Department of Health and Social Care

## Explanatory note

(This note is not part of the Regulations)
These Regulations amend the Branded Health Service Medicines (Costs) Regulations 2018 (S.I. 2018/345) (the “Statutory Scheme Regulations”). The Statutory Scheme Regulations, amongst other matters, make a scheme for the purpose of requiring specific manufacturers and suppliers of branded medicines for health service use to pay certain amounts to the Secretary of State. These amounts are calculated by reference to the net sales income or estimated net sales income from supplies of such medicines. These amendments update the payment percentages for 2026 and subsequent years.
Regulation 2(2) makes provision to replace the newer presentation payment percentages in the table in regulation 3(1) of the Statutory Scheme Regulations with new payment percentages applicable to net sales income to be payable from 1st July 2026 for each applicable period.
Regulation 2(3) and (4) amend paragraphs (1AB) and (1AC) of regulation 3 of the Statutory Scheme Regulations. The amendments update the payment percentages to be paid by manufacturers or suppliers who have paid the higher rate of 24.3% on their supplies during the first half of 2026 and will pay a reduced rate of 8.7% from 1st July 2026 to 31st December 2026 to account for the higher rate they have paid on supplies during the first 6 months of 2026. The rate of 8.7% is instead of the 16.5% as stated in the table at regulation 3(1) which would otherwise apply.
An impact assessment relating to this instrument has been prepared and copies can be obtained from the Department of Health and Social Care, 39 Victoria Street, London, SW1H 0EU and is available on the www.legislation.gov.uk website.

---
Source: https://www.legislation.gov.uk/uksi/2026/614 (the official version)
Page: https://openlegislation.uk/branded-health-service-medicines-costs-amendment-regulations-2026
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.